Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Eisai Launches Halaven in Brazil
November 26, 2014
- Eisai Launches Fycompa in Hong Kong
November 26, 2014
- MSD Seeks Japan Regulatory Approval for Once-Weekly DPP-4 Inhibitor
November 25, 2014
- Rushed Settlements Dragged Down Drug Delivery Prices: Vital KSK Exec
November 25, 2014
- Merck Serono Transfers Marketing Rights for Saizen to Fujifilm Pharma
November 25, 2014
- Top Two Japan Universities to Offer Undergrads Amgen-Sponsored Lab Experience Programs
November 21, 2014
- Domestic Subgroup Analysis Confirms Efficacy of Cimzia: Astellas, UCB Japan
November 21, 2014
- Kissei Files NDA for Hyperphosphatemia Treatment in Japan
November 21, 2014
- CareNet Teams Up with Indian Firm on Marketing Solutions for Drug Makers
November 20, 2014
- Ranbaxy Sues FDA for Revoking Tentative Approvals for Nexium, Valcyte Generics
November 20, 2014
- Takeda Ordered to Pay US$155,000 for Spoliation of Evidence in Actos Case
November 20, 2014
- Nipro Pharma Joins Hands with Thai Firm on Drug Distribution
November 20, 2014
- Mirena Approved for Dysmenorrhea Based on Data from Public Domain: Bayer Yakuhin
November 20, 2014
- 30% of Pharmacies Handling Blopress AGs Likely to Use Other Makers’ Generics: Survey
November 19, 2014
- Topical Combination Agent for Plaque Psoriasis Showed Superiority to Monotherapies in PIII Trial: Maruho
November 19, 2014
- Giotrif Extends Overall Survival in Japanese NSCLC Patients with Del19 EGFR Mutation: NBI
November 19, 2014
- Valtrex Adult Indications Approved for Children: GSK
November 19, 2014
- Inderal Tablets Approved for Prevention of Hypoxic Episodes: AZ
November 19, 2014
- RaQualia’s Acid Pump Antagonist Enters Domestic PI Study
November 18, 2014
- Diet and Exercise Regimens Weigh on Type 2 Diabetes Patients: MSD Poll
November 18, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…